11 Participants Needed

Lenvatinib + Everolimus for Kidney Cancer

Yousef Zakharia, MD profile photo
Overseen ByYousef Zakharia, MD
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Yousef Zakharia
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The purpose of this research study is to see what effect the combination of lenvatinib plus everolimus has in local and metastatic renal cell carcinoma to potentially make surgically unresectable tumors resectable.

Research Team

Yousef Zakharia, M.D. - Doctors and ...

Yousef Zakharia, MD

Principal Investigator

University of Iowa

Eligibility Criteria

Adults with advanced or metastatic renal cell carcinoma, clear cell type, who may undergo surgery. They must have normal kidney function or mild impairment, acceptable blood counts and liver enzymes, an ECOG performance status of 0-2 (meaning they can care for themselves), a life expectancy over 12 weeks, measurable disease by medical imaging, and a heart ejection fraction ≥45%. Men and women must use contraception; women need a negative pregnancy test.

Inclusion Criteria

Your liver function test results (AST/ALT) are within the normal range.
I am not pregnant and agree to use two forms of birth control.
I am a man who can father a child and agree to use birth control.
See 9 more

Exclusion Criteria

Your cholesterol and triglyceride levels are very high when you haven't eaten for a while.
Subject that is pregnant or lactating
I have been cancer-free from another type for less than 3 years.
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2 weeks
1 visit (in-person)

Treatment

Participants receive lenvatinib and everolimus for 8 weeks, followed by a 1-week washout period

9 weeks
Weekly visits (in-person)

Surgery

Participants undergo nephrectomy surgery after the washout period

1 week
1 visit (in-person)

Follow-up

Participants are monitored for surgical complications and disease status

5 years
Monthly visits if metastatic disease, every three months if no evidence of disease

Treatment Details

Interventions

  • Everolimus
  • Lenvatinib
  • Partial or Radical Cytoreductive Nephrectomy
Trial Overview The trial is testing the combination of two drugs: lenvatinib plus everolimus in patients with local and metastatic renal cell carcinoma. The goal is to see if this drug combo can shrink tumors enough to make them operable when they previously weren't considered so.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Lenvatinib and Everolimus prior to cytoreductive nephrectomyExperimental Treatment3 Interventions
Eligible patients will start treatment with lenvatinib 18 mg PO daily (administered as one 10 mg capsule and two 4 mg capsules) and everolimus 5 mg PO daily for 4 weeks constituting one cycle. Two cycles of treatment will be administered and after 2 weeks wash out period, the patients will go for nephrectomy.

Everolimus is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Afinitor for:
  • Advanced renal cell carcinoma
  • Subependymal giant cell astrocytoma
  • Progressive neuroendocrine tumors of pancreatic origin
  • Advanced hormone receptor-positive, HER2-negative breast cancer
  • Tuberous sclerosis complex-associated partial-onset seizures
🇪🇺
Approved in European Union as Votubia for:
  • Subependymal giant cell astrocytoma
  • Renal angiomyolipoma
  • Tuberous sclerosis complex-associated partial-onset seizures
🇺🇸
Approved in United States as Zortress for:
  • Prevention of organ rejection in kidney transplant patients

Find a Clinic Near You

Who Is Running the Clinical Trial?

Yousef Zakharia

Lead Sponsor

Trials
5
Recruited
160+

Eisai Inc.

Industry Sponsor

Trials
524
Recruited
161,000+
Founded
Eisai Inc. was established in 1995 as the U.S. subsidiary of Eisai Co., Ltd.
Headquarters
Woodcliff Lake, NJ, USA
Known For
Neurology and Oncology
Top Products
Aricept (donepezil), Lenvima (lenvatinib), Leqembi (lecanemab), Halaven (eribulin)
Lynn Kramer profile image

Lynn Kramer

Eisai Inc.

Chief Medical Officer since 2019

MD

Tatsuyuki Yasuno profile image

Tatsuyuki Yasuno

Eisai Inc.

Chief Executive Officer since 2023

MBA from Kellogg School of Management, Northwestern University; Bachelor of Political Science from Waseda University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security